- Home
- EVER vs ADPT Comparison
EVER vs ADPT Comparison
Compare EVER & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVER
- ADPT
- Stock Information
- Founded
- EVER 2008
- ADPT 2009
- Country
- EVER United States
- ADPT United States
- Employees
- EVER N/A
- ADPT N/A
- Industry
- EVER Computer Software: Programming Data Processing
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVER Technology
- ADPT Health Care
- Exchange
- EVER Nasdaq
- ADPT Nasdaq
- Market Cap
- EVER 960.3M
- ADPT 1.1B
- IPO Year
- EVER 2018
- ADPT 2019
- Fundamental
- Price
- EVER $22.70
- ADPT $7.33
- Analyst Decision
- EVER Strong Buy
- ADPT Strong Buy
- Analyst Count
- EVER 6
- ADPT 5
- Target Price
- EVER $32.33
- ADPT $9.40
- AVG Volume (30 Days)
- EVER 688.7K
- ADPT 2.4M
- Earning Date
- EVER 05-05-2025
- ADPT 05-01-2025
- Dividend Yield
- EVER N/A
- ADPT N/A
- EPS Growth
- EVER N/A
- ADPT N/A
- EPS
- EVER 0.88
- ADPT N/A
- Revenue
- EVER $500,190,000.00
- ADPT $178,957,000.00
- Revenue This Year
- EVER $27.51
- ADPT $21.20
- Revenue Next Year
- EVER $11.88
- ADPT $22.06
- P/E Ratio
- EVER $25.73
- ADPT N/A
- Revenue Growth
- EVER 73.72
- ADPT 5.10
- 52 Week Low
- EVER $16.63
- ADPT $2.28
- 52 Week High
- EVER $30.03
- ADPT $9.01
- Technical
- Relative Strength Index (RSI)
- EVER 42.77
- ADPT 43.94
- Support Level
- EVER $19.70
- ADPT $7.38
- Resistance Level
- EVER $22.98
- ADPT $8.30
- Average True Range (ATR)
- EVER 1.54
- ADPT 0.75
- MACD
- EVER -0.34
- ADPT -0.04
- Stochastic Oscillator
- EVER 31.71
- ADPT 33.85
About EVER EverQuote Inc.
EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).